Please login to the form below

Not currently logged in
Email:
Password:

AbbVie’s JAK inhibitor Rinvoq approved in EU for rheumatoid arthritis

Continued expansion for next-generation immunology drug

Rinvoq


AbbVie’s JAK inhibitor Rinvoq has been approved by the European Commission for the treatment of moderate-to-severe rheumatoid arthritis. 

It will now be available for adult rheumatoid arthritis (RA) patients across Europe, who have not responded to or are intolerant to at least one disease-modifying anti-rheumatic drug.

AbbVie needs a next-generation immunology drug to counteract the offset from declining sales of its ageing immunology blockbuster Humira (adalimumab).

The pharma company has been pushing Rinvoq (upadacitinib) into the RA market, while its Boehringer Ingelheim-partnered drug Skyrizi (risankizumab) has been making headway in psoriasis.

The approval of Rinvoq in RA was supported by data from the phase 3 SELECT programme, which evaluated almost 4,400 patients with moderate-to-severe active RA across five studies.

Across these phase 3 studies, Rinvoq met all its primary and secondary endpoints. Low disease activity and clinical remission rates were consistent across the patient populations.

“We are proud to offer this once-daily tablet as a new treatment option for patients with moderate-to-severe active rheumatoid arthritis,” said Michael Severino, vice chairman and president of AbbVie.

“As a company that has been dedicated to discovering and delivering transformative therapies for people living with rheumatic diseases for nearly two decades, Rinvoq expands our portfolio of treatment options for people living with this disease in Europe,” he added.

The approval in Europe will be come as some much-needed good news for AbbVie, after US cost-effectiveness watchdog ICER recently released a report that concluded Rinvoq has only a ‘marginal clinical benefit’ over Humira, but with a more costly price tag.

In a head-to-head trial of the two drugs, Rinvoq demonstrated statistically significant higher rates of disease remission and improvement in other outcomes when compared to Humira – however, ICER said the benefit was only ‘modest’.

ICER also presented concerns over the long-term impact of next-generations drug treatments for RA, although many have criticised its methods of determining benefit.

This includes a number of patient organisations who argue that drugs like Rinvoq and Pfizer’s JAK inhibitor Xeljanz (tofacitinib) have created real improvements for people living with the condition.

Article by
Lucy Parsons

19th December 2019

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...